AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 271 min read$CRL

FOSTER JAMES C sold $10.1M of CRL

FOSTER JAMES C sold 33,561 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $300.00 ($10.07M total) on 2026-08-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FOSTER JAMES C
Published Aug 27, 2026, 8:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 10:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CRL
Bearish
medium confidence
Mentioned
$CRL
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRLBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, which traders may use to adjust short‑term positions.

02

Market read

Insider sell of $10M by a director is a modestly material event for CRL, offering a low‑to‑moderate trading signal.

03

What to watch

Potential upcoming earnings or product news that could offset the sell pressure.

Relevance 6/10Novelty 8/10Timing: post‑market 2026‑08‑25

Background

Form 4 filings disclose insider transactions and are primary sources of new corporate information.

Company-level read

Ticker impact

$CRLBearishMedium confidence
Context

Director Foster James C sold 33,561 shares for $10.07M via a 10b5‑1 plan on 2026‑08‑25.

Expected impact

Potential modest downside pressure in the next trading session.

Evidence & confidence

A $10M sale by a director is material for a mid‑cap biotech, but not large enough to trigger a major move.

Market effects

Sector

May raise concerns for the biotech services sector if other insiders follow suit.

Regional

Limited to US markets where CRL trades.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to fundamentals.

Key entities

  • Company
    Charles River Laboratories International, Inc.

    Provider of laboratory services and products to the pharmaceutical and biotech industries.

  • Individual
    Foster James C.

    Director of Charles River Laboratories who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRL insider trading history →

Related articles

AUG 21
$ACBHighAI 8/10

Aurora Snipes Back At Curaleaf’s Hostile Bid

Aurora Cannabis rejected Curaleaf's hostile $4 per share bid, urging shareholders to take no action. Curaleaf claims its offer represents a 45% premium over Aurora's 30-day average share price. Aurora's shares rose 34% to $3.89, while Curaleaf's OTC shares gained 6% to $9.80. Aurora's board formed a special committee to review the offer, which expires on December 1.

yahoo.com2 min
AUG 19
$AMLXHighAI 8/10

Biotech Stocks At 52-Week Highs - AMLX +63% With Phase 3 Data, VOGX +25%, OBIO +19%, ATRC, CRL

Several biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.

rttnews.com3 min
AUG 14
$CRLMed

Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript

Charles River Laboratories (CRL) reported Q2 2026 results, citing a strengthening biopharmaceutical demand environment. DSA net book-to-bill rose to nearly 1.2x for a third straight quarter above 1x. Organic revenue growth returned to 0.1%. Operating margin improved 420 bps sequentially to 20.5% after divestitures. CRL also announced collaborations with Eli Lilly (TuneLab) and Arovella Therapeutics (NGS).

yahoo.com6 min
AUG 9
$CRLMed

Charles River Laboratories International (CRL) Cuts Guidance, Is It Still Undervalued?

Charles River Laboratories International (CRL) cut its 2026 GAAP earnings guidance and reported a quarterly net loss, citing divestiture-related charges and slightly lower revenue year over year. The article notes strong recent share performance and presents two valuation views, including a $313.61 fair value versus a $267.49 last close, plus a planned $510M acquisition of K.F. (Cambodia) Ltd.

simplywall.st6 min
AUG 7
$CRLMed

Charles River (CRL) Lifts Adjusted EPS Outlook After DSA Beat and Divestiture Hit Has The Bull Case Changed?

Charles River Laboratories (CRL) reported Q2 2026 revenue of $1,004.08M and a GAAP net loss of $1.48M. The company cut 2026 GAAP EPS guidance to $3.05 to $3.35 per share due to divestiture-related losses, but raised full-year adjusted (non-GAAP) EPS after DSA results beat expectations, citing margin potential and lower non-human primate sourcing costs.

simplywall.st6 min